Pulmonary vascular disease & thromboembolism
Proteomic Signatures of Right Ventricular Outcomes in Pulmonary Arterial Hypertension
Authors' conclusion
Distinct plasma proteomic profiles are associated with mortality, RV dilation, and NT-proBNP in PAH.
Study context
- Population
- Patients with pulmonary arterial hypertension
- Participants
- 117 patients
- Exposure
- Plasma proteome by mortality, right ventricular (RV) dilation and NT-proBNP level
- Outcome
- Proteomic features and pathways associated with mortality, RV dilation and NT-proBNP
- Follow-up
- 3 years
Methodological detailssingle-institution, 3 years of follow-up, plasma proteomic profiling (7288 aptamers), external validation in independent pulmonary arterial hypertension (PAH) cohorts
- Single-institution
- 3 years of follow-up
- Plasma proteomic profiling (7288 aptamers)
- External validation in independent PAH cohorts
Main finding
As reported in the abstract
- Clear proteome separation between survivors and nonsurvivors, dilated vs nondilated RV, and across NT-proBNP levels
- ECM proteins and pathways upregulated in those who died, with severe RV dilation, and with higher NT-proBNP
- After pulmonary vascular resistance adjustment, ECM proteins associated with RV vulnerability independent of afterload
- Findings confirmed in independent PAH cohorts (plasma proteomics, RV tissue gene and protein expression)
Observational data: associations, not effects.
Original publication
Proteomic Signatures of Right Ventricular Outcomes in Pulmonary Arterial Hypertension. Circ Heart Fail. Published 22 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →